← Back to Clinical Trials
Recruiting NCT04587856
Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients
Trial Parameters
Condition Myelodysplastic Syndromes
Sponsor Gruppo Italiano Malattie EMatologiche dell'Adulto
Study Type INTERVENTIONAL
Phase N/A
Enrollment 38
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2021-02-12
Completion 2025-03
Interventions
bone marrow withdrawal
Brief Summary
This is a biological study for adult MDS patients who undergo HSCT procedure. Viable bone marrow samples will be collected and cryopreserved from MDS patients before transplantation and at clinical disease recurrence. CD34+ blast cells at disease relapse after HSCT will be compared with CD34+ cells collected before transplant to study genomic and transcriptomic changes.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of MDS according to 2016 WHO criteria * Aged 18y or older * Patients who will receive allogeneic stem cell transplantation (HSCT) * Signed written informed consent according to ICH/EU/GCP and national local laws Exclusion Criteria: * Second HSCT procedure.
Related Trials
NCT05875805
A Telehealth Advance Care Planning Intervention
View Trial →
NCT06956755
Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia
View Trial →
NCT07238686
Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS
View Trial →